CO6660466A2 - Métodos, composiciones y equipos para el tratamiento de los transtornos de mineralización en la matriz osea - Google Patents

Métodos, composiciones y equipos para el tratamiento de los transtornos de mineralización en la matriz osea

Info

Publication number
CO6660466A2
CO6660466A2 CO12217161A CO12217161A CO6660466A2 CO 6660466 A2 CO6660466 A2 CO 6660466A2 CO 12217161 A CO12217161 A CO 12217161A CO 12217161 A CO12217161 A CO 12217161A CO 6660466 A2 CO6660466 A2 CO 6660466A2
Authority
CO
Colombia
Prior art keywords
treatment
bone matrix
compositions
equipment
matrix mineralization
Prior art date
Application number
CO12217161A
Other languages
English (en)
Inventor
Philippe Crine
Pierre Leonard
Original Assignee
Alexion Pharma Internat Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Internat Sarl filed Critical Alexion Pharma Internat Sarl
Publication of CO6660466A2 publication Critical patent/CO6660466A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos, composiciones y equipos para el tratamiento de los trastornos de la mineralización de la matriz ósea tales como la hipofosfatasia. En particular, la presente invención proporciona polipéptidos que tienen una fosfatasa alcalina soluble fusionada a un dominio o región Fc de una inmunoglobulina. Tales polipéptidos se pueden administrar a pacientes, por ejemplo, por vía subcutánea, para tratar la hipofosfatasia usando terapia de sustitución enzimática. La invención también incluye ácidos nucleicos que codifican tales polipéptidos y el uso de los ácidos nucleicos para el tratamiento de trastornos de mineralización de la matriz ósea.
CO12217161A 2010-04-30 2012-11-29 Métodos, composiciones y equipos para el tratamiento de los transtornos de mineralización en la matriz osea CO6660466A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32987710P 2010-04-30 2010-04-30

Publications (1)

Publication Number Publication Date
CO6660466A2 true CO6660466A2 (es) 2013-04-30

Family

ID=44860717

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12217161A CO6660466A2 (es) 2010-04-30 2012-11-29 Métodos, composiciones y equipos para el tratamiento de los transtornos de mineralización en la matriz osea

Country Status (14)

Country Link
US (1) US9988620B2 (es)
EP (1) EP2563406A4 (es)
JP (1) JP5986986B2 (es)
KR (1) KR20130118203A (es)
CN (1) CN103153344A (es)
AU (1) AU2011245005A1 (es)
BR (1) BR112012027765A2 (es)
CA (1) CA2797865A1 (es)
CO (1) CO6660466A2 (es)
EA (1) EA201291138A1 (es)
IL (1) IL222695A0 (es)
MX (1) MX2012012643A (es)
SG (1) SG185079A1 (es)
WO (1) WO2011134084A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3404102T3 (da) 2004-04-21 2021-09-06 Alexion Pharma Inc Knogletilførselskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
CA2797865A1 (en) 2010-04-30 2011-11-03 Alexion Pharma International Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN111778228A (zh) * 2014-01-24 2020-10-16 安-法玛公司 嵌合型碱性磷酸酶样蛋白
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
MX2018011833A (es) * 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289A4 (en) 2016-08-18 2020-05-06 Alexion Pharmaceuticals, Inc. METHODS OF TREATING TRACHEOBRONCHOMALACIA
JP7142021B2 (ja) * 2017-03-09 2022-09-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質製造プロセス
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US20200316178A1 (en) * 2017-10-26 2020-10-08 Shire Human Genetic Therapies, Inc. Formulations comprising glucocerebrosidase and isofagomine
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN109061129B (zh) * 2018-06-08 2022-11-29 中山大学附属口腔医院 钛表面纳米管仿生矿化方法及用于该方法的试剂盒与溶液
CA3161266A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3173962A1 (en) * 2020-09-04 2022-03-10 Anna PETRYK Methods for treating bone mineralization disorders
BR112023016048A2 (pt) * 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
WO1995005455A1 (en) 1993-08-13 1995-02-23 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
JPH0870875A (ja) 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2262056A1 (en) 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
AU772074B2 (en) 1999-04-28 2004-04-08 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
DE60034478T2 (de) 1999-11-16 2008-01-10 Genzyme Corp., Cambridge Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
EP1248790A1 (en) 1999-12-17 2002-10-16 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
AU2001287429B2 (en) 2000-08-23 2005-08-18 Alexion Pharmaceuticals, Inc. Method and compositions for promoting osteogenesis
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
ATE437221T1 (de) 2001-05-14 2009-08-15 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
US20030158132A1 (en) 2002-01-22 2003-08-21 Genvec, Inc. Method for enhancing bone density or formation
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
AU2004257142A1 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
DK3404102T3 (da) 2004-04-21 2021-09-06 Alexion Pharma Inc Knogletilførselskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle
US20070081986A1 (en) 2005-10-07 2007-04-12 Shunji Tomatsu Beta-glucuronidase with an attached short peptide of acidic amino acids
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006039480A2 (en) 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
WO2006060641A2 (en) 2004-12-01 2006-06-08 Genzyme Corporation Methods for targeted delivery of genetic material to the liver
US20070042957A1 (en) 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
US7803901B2 (en) 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
AU2007315790A1 (en) 2006-06-30 2008-05-08 Interface Biologics, Inc. Bioresponsive polymers
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
BR122019000505B1 (pt) 2007-05-11 2022-01-18 Alexion Pharmaceuticals, Inc Fosfatase alcalina direcionada ao osso, kits e métodos de seu uso
WO2008154226A1 (en) 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
EP2190466A4 (en) 2007-08-10 2011-12-21 Burnham Inst Medical Research Tissue-specific alkaline phosphatase (TNAP) activators and their use
KR20100057063A (ko) 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
KR20190128002A (ko) * 2008-06-26 2019-11-13 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
EP3175863B1 (en) 2009-05-20 2021-12-01 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
CA2797865A1 (en) 2010-04-30 2011-11-03 Alexion Pharma International Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders

Also Published As

Publication number Publication date
KR20130118203A (ko) 2013-10-29
WO2011134084A8 (en) 2012-12-06
US20130108635A1 (en) 2013-05-02
BR112012027765A2 (pt) 2019-09-24
JP2013525379A (ja) 2013-06-20
WO2011134084A1 (en) 2011-11-03
AU2011245005A1 (en) 2012-11-22
US9988620B2 (en) 2018-06-05
CA2797865A1 (en) 2011-11-03
MX2012012643A (es) 2013-01-22
EA201291138A1 (ru) 2013-05-30
CN103153344A (zh) 2013-06-12
EP2563406A4 (en) 2013-11-13
EP2563406A1 (en) 2013-03-06
IL222695A0 (en) 2012-12-31
SG185079A1 (en) 2012-12-28
JP5986986B2 (ja) 2016-09-06

Similar Documents

Publication Publication Date Title
CO6660466A2 (es) Métodos, composiciones y equipos para el tratamiento de los transtornos de mineralización en la matriz osea
CL2020003392A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
MX2015011873A (es) Dominios gla como agentes de direccionamiento.
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
MY188139A (en) Sodium channel modulators for the treatment of pain
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
AR089993A1 (es) Macrociclos peptidomimeticos
BR112014009418A2 (pt) macrociclos peptidomiméticos
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
UY33219A (es) Cetoenoles cíclicos para terapias
AR092736A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
CR20150638A (es) Marcador para trastornos de la esfingomielinasa ácida y sus usos
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf

Legal Events

Date Code Title Description
FC Application refused